Industry groups have identified upfront costs as a barrier to streamlining U.S. drugmaking. The nonprofit API Innovation Center has a proposed answer for how to tilt finances in favor of investments ...

With a substantial manufacturing base already locked down in China, CRDMO BioDuro is taking a short jaunt down to Taiwan for its latest drug ingredients production play.  | BioDuro, headquartered in ...

The MarketWatch News Department was not involved in the creation of this content. The global industry was valued at US$ 38.9 Bn in 2022 and is expected to register a CAGR of 7.1% from 2023 to 2031.

Construction is scheduled to commence in spring 2026, with both facilities anticipated to be fully operational by 2029.

EAST RUTHERFORD, N.J., Oct. 22, 2025 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced a $120 million investment to expand its U.S.

ESTEVE CDMO, a global CDMO specializing in high-quality small-molecule APIs and pharmaceutical intermediates, began a $15.5 ...

Eli Lilly and Company (Lilly) plans to construct an active pharmaceutical ingredient (API) manufacturing facility, totaling around 1 million square feet, in Harris County, Texas. According to news ...

Amazon Filters is a leading manufacturer of bespoke filter housings and high-performance filter media used in the manufacture of Active Pharmaceutical Ingredients (API's) - vital building blocks for ...

Pakistan's pharmaceutical industry, valued at Rs. 748 billion, faces challenges with API imports. Localizing API production could enhance economic stability and healthcare affordability.

HAMBURG, GERMANY / ACCESSWIRE / November 5, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) has announced the sale of its chemical API manufacturing site, ...